人民财讯8月1日电,艾伯维近日宣布,upadacitinib(RINVOQ®)治疗斑秃的UP-AA临床研究中两项关键性研究中的第一项取得积极结果。该研究评估了upadacitinib(RINVOQ®,15mg和30mg,每日一次)在成人和青少年重度斑秃(AA)患者中的安全性与有效性。受试者的基线平均SALT评分为83.8(约等于16%的头皮毛发覆盖率)。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.